Different clinical effects upon separate inhibition of coexisting EGFR and PI3KCA mutations in a lung adenocarcinoma patient. Issue 2 (February 2015)

• Record Type: Journal Article
• Authors: Tiseo, Marcello; Bersanelli, Melissa; Perrone, Federica; Tamborini, Elena; Settanni, Giulio; Busico, Adele; Rossi, Giulio; Ardizzoni, Andrea; Pelosi, Giuseppe
• Is Part Of: Lung cancer. Volume 87:Issue 2(2015:Feb.)
• Page Start: 204
• Page End: 206
• Publication Date: 2015-02
• Subjects: NSCLC -- EGFR -- PI3KCA -- Gene mutations -- Erlotinib -- PI3K inhibitor; Lungs -- Cancer -- Periodicals; Lung Neoplasms -- Abstracts; Lung Neoplasms -- Periodicals; Poumons -- Cancer -- Périodiques; Lungs -- Cancer; Periodicals; Electronic journals; Electronic journals; 616.99424
• DOI: 10.1016/j.lungcan.2014.12.008
• Languages: English
• ISSNs: 0169-5002

Abstract

Highlights: Mutations of PIK3CA characterize 2–4% of NSCLC. PIK3CA mutations are not-mutually-exclusive with other mutations. Shorter median survival was reported if concomitant PIK3CA and EGFR mutations. In this case, progression disease was reported with PI3K inhibitor. Benefit with EGFR-TKI is possible also with concomitant PIK3CA and EGFR mutations. Abstract: We present a very interesting case of lung adenocarcinoma carrying an uncommon EGFR exon 19 insertion with concomitant PIK3CA mutation showing dramatic and persisting improvement upon erlotinib therapy, after progression during PI3K inhibitor.